RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

NCT07416474 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

574

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: RC148 plus Carboplatin and Paclitaxel
DRUG: Tislelizumab plus Carboplatin and Paclitaxel

Sponsor

RemeGen Co., Ltd.